Candel Therapeutics (formerly known as Advantagene) is a biopharmaceutical company developing cancer immunotherapies. It develops CAN-2409, a gene-mediated cytotoxic immunotherapy (GMCI), a platform technology designed to stimulate a patient’s immune system to naturally fight against cancer. The company also engineers CAN-3110, an oncolytic herpes simplex viral (HSV) vector, for recurrent glioblastoma treatment.